ALAFI CAPITAL CO LLC - 19 Aug 2026 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Reporting relationship: 10%+ Owner
Issuer ticker: CALC
Reported as of: 19 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Aug 2026, 17:03:15 UTC
Prior SEC filing: 10 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher D. Alafi, as managing member of Alafi Capital Company, LLC

Key filing fact

ALAFI CAPITAL CO LLC filed Form 4 for CalciMedica, Inc. (CALC) on 24 Aug 2026.

Key facts

This page summarizes ALAFI CAPITAL CO LLC's Form 4 filing for CalciMedica, Inc. (CALC).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 24 Aug 2026, 17:03.

Change

Previous filing in this sequence was filed on 10 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001216017 Primary reporting owner

ALAFI CAPITAL CO LLC

Relationship: 10%+ Owner
Address: 8 ADMIRAL DRIVE, SUITE 324, EMERYVILLE
Signature: /s/ Christopher D. Alafi, as managing member of Alafi Capital Company, LLC
Signature date: 24 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CALC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,112,345
Date: 19 Aug 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CALC transaction Derivative

Series A Warrants

Award

Transaction value
Shares: +3,529,192
Change %
Price: $0.000000^*
Shares after: 3,529,192
Date: 19 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,529,192
Exercise price: $0.8033
Footnotes: F1, F2

CALC transaction Derivative

Series B Warrants

Award

Transaction value
Shares: +3,529,192
Change %
Price: $0.000000^*
Shares after: 3,529,192
Date: 19 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,529,192
Exercise price: $1.00
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The issue date of the Series A Warrants is August 19, 2026.

Footnote F2

The expiration of these Series A Warrants is the earlier of (i) 18 months after the closing date of the Private Placement and (ii) 30 days following the Issuer's public announcement of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480.

Footnote F3

The issue date of the Series B Warrants is August 19, 2026.